Investigational drug · Phase 3
Pre-screening Phase
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Soil-Transmitted Helminths.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
334
Any phase or sponsor naming "Pre-screening Phase"
First trial start
2025
Sep 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pre-screening Phase", any sponsor or status.
Conditions studied
As listed on its trial records.
- Soil-Transmitted Helminths
Largest trials
Live from ClinicalTrials.gov: studies naming "Pre-screening Phase" as an intervention, largest first.
- Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and EffectivenessPivotal-lookingRecruiting
Insud PharmaIndustry
NCT06282315 · 20,000 participants (planned) · Start Sep 1, 2025 · Primary completion Apr 2026
Drug: Pre-screening Phase; Screenig Phase and 6 more · For: Soil-Transmitted Helminths
Sites: Accra, Ghana; Nairobi, Kenya
Persephone BiosciencesIndustry
NCT04638751 · 5,000 participants (planned) · Start Jul 1, 2022 · Primary completion Dec 31, 2028
Drug: Immunotherapy; Chemotherapy · For: Non-small Cell Lung Cancer; Colorectal Cancer; Triple Negative Breast Cancer and 1 more
Sites: Orange, California; San Diego, California; Miami, Florida · 10 sites in all
- Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity SyndromePivotal-lookingStatus unknown
Shandong Provincial Institute of Dermatology and VenereologyAcademic, hospital or other
NCT02550080 · 3,130 participants (planned) · Start Jul 2015 · Primary completion Dec 2018
Drug: Dapsone · For: Allergic Cutaneous Vasculitis; Urticaria; Psoriasis and 5 more
Sites: Jinan, China
- Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPDPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02165826 · 1,323 participants · Start May 1, 2014 · Primary completion Sep 1, 2015
Drug: Roflumilast; Roflumilast Placebo and 1 more · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Bardejov, Slovakia; Spišská Nová Ves, Slovakia
- A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)Pivotal-lookingStatus unknown
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT00262067 · 1,237 participants · Start Dec 2005 · Primary completion Jul 2008
Drug: Bevacizumab; Placebo and 1 more · For: Metastatic Breast Cancer
Sites: Fullerton, California; Santa Barbara, California; Iowa City, Iowa · 92 sites in all
- Detection of False Positives From First-trimester Preeclampsia Screening (StopPRE) at the Second-trimester of PregnancyPivotal-lookingCompleted
Hospital Universitari Vall d'Hebron Research InstituteAcademic, hospital or other
NCT03741179 · 974 participants · Start Aug 20, 2019 · Primary completion Jan 30, 2022
Drug: ASA-withdrawn group · For: Pre-Eclampsia
Sites: Barcelona, Spain
- A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 DiabetesPivotal-lookingActive, not recruiting
CSPC Ouyi Pharmaceutical Co., Ltd.Industry
NCT07026968 · 815 participants (planned) · Start Jun 20, 2025 · Primary completion Oct 30, 2026
Drug: Prusogliptin, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR; Prusogliptin placebo, Dapagliflozin(high dose), Dapagliflozin (low dose) placebo, plus metformin XR and 3 more · For: Type 2 Diabetes
Sites: Shijiazhuang, China
- Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)Pivotal-lookingTerminated
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT00767000 · 813 participants · Start Oct 2008 · Primary completion Apr 2010
Drug: MK-0941; Comparator: Placebo and 2 more · For: Diabetes Mellitus, Type 2
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of CarePivotal-lookingTerminated
Lakefront Biotherapeutics NVIndustry
NCT03733444 · 781 participants · Start Nov 5, 2018 · Primary completion Mar 30, 2021
Drug: GLPG1690; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 132 sites in all
- Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity DisorderPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01074294 · 740 participants · Start Mar 16, 2010 · Primary completion Jun 20, 2011
Drug: OPDC-34712; Placebo and 1 more · For: Attention Deficit Hyperactivity Disorder
Sites: Little Rock, Arkansas; Beverly Hills, California; Irvine, California · 35 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Multimodal pre-screening can predict BCI performance variability: A novel subject-specific experimental scheme.
Borgheai SB, Zisk AH, McLinden J, et al. · Comput Biol Med 2024
- Possible risk compensation, attitudes, and beliefs among Brazilian individuals potentially eligible for pre-exposure prophylaxis.
Villela LM, Veloso VG, Hoagland B, et al. · Int J STD AIDS 2021
- Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis.
Ansart M, Epelbaum S, Gagliardi G, et al. · Stat Methods Med Res 2020
- Instructional Demonstrations are More Efficient Than Consequences Alone for Children with Naming.
Hranchuk K, Douglas Greer R, Longano J · Anal Verbal Behav 2019
- Early diagnosis and detection of breast cancer.
Milosevic M, Jankovic D, Milenkovic A, et al. · Technol Health Care 2018
- Evaluating FINDRISC as a screening tool for type 2 diabetes among overweight adults in the PREVIEW:NZ cohort.
Silvestre MP, Jiang Y, Volkova K, et al. · Prim Care Diabetes 2017
Also in development for Soil-Transmitted Helminths
- Screenig PhasePhase 31 trial
Insud Pharma · Soil-Transmitted Helminths
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.